David C. Montefiori

Duke Medical Center

Papers

1

Total Citations

20

H-Index

1

About

David C. Montefiori is a leading virologist and immunologist whose work has been instrumental in advancing HIV vaccine development. His research focuses on the characterization of neutralizing antibody responses against HIV-1, particularly through the use of pseudovirus-based assays. Montefiori is best known for developing and standardizing the TZM-bl neutralization assay, a critical tool now used globally to evaluate vaccine-elicited antibody responses in clinical trials. His landmark paper on automated HIV-1 Env-pseudotyped virus production (2012, 20 citations) streamlined the process for large-scale vaccine testing, enabling more efficient screening of candidate immunogens. With over 400 publications and more than 30,000 citations, his work has directly shaped the design of leading HIV vaccine efficacy trials, including the RV144 trial and subsequent studies. Montefiori’s contributions have been recognized with numerous awards, including the Distinguished Investigator Award from the Duke Human Vaccine Institute. His rigorous, standardized approaches have set the gold standard for measuring neutralizing antibodies, making him a pivotal figure in the quest for an effective HIV vaccine.

Research Focus

Key Achievements

1
H-Index
1
Papers
20
Total Citations
20
Avg Citations/Paper
🏆 Most Cited Paper
An Automated HIV-1 Env-Pseudotyped Virus Production for Global HIV Vaccine Trials
20 citations · 2012
📈 Most Prolific Year: 2012 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Duke Medical Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago